跳至主要内容
临床试验/NL-OMON50983
NL-OMON50983招募中3 期

Rediscovery of metformin for the chronic disabling auto-inflammatory disease hidradenitis suppurativa - Metformin in HS

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 62 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
62

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Age >=18 years at baseline
  • A diagnosis of HS for at least 1 year prior to baseline
  • mild to moderately active disease defined by a HS Physician Global Assessment
  • score of 2-3 and the Refined Hurley classification of mild to moderate
  • at baseline
  • Indication for systemic therapy; i.e. uncontrolled disease under conventional
  • topical therapy.
  • Able and willing to give written informed consent and to comply with the
  • study requirements.

排除标准

  • Pregnant and lactating women
  • Previously diagnosed diabetes mellitus and receiving active treatment
  • Use of oral antibiotics within 14 days prior to baseline
  • Use of immunosuppressing/modulating therapies within 28 days prior to baseline
  • A known allergy to metformin or doxycycline or any of the ingredients
  • metformin or doxycycline
  • Contraindications for the use of either metformin (e.g. acute metabolic
  • acidosis, or severe
  • kidney failure with a creatinine clearance < 30 ml/min) or doxycycline
  • (severe liver function

研究者

相似试验